Different SGLT‐2is have undergone extensive evaluation in various cardiovascular outcome trials (CVOTs); however, as these studies only address patients with T2DM, the late‐breaking question has been if SGLT‐2is will confer equal or varying benefits when used as an adjunct treatment to insulin in T1DM. The gene discussed is INS; the disease is type 1 diabetes mellitus.